ARCHIVES

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

This article is from The Cancer Letter archive.

Vol. 34 No. 9 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

Deep Budget Cuts Poised to Kick in March 1; Hill Insiders See Little Hope for Deal

February 15, 2013

First Compound From New In Vitro Screening to Enter Clinical Trials

December 5, 1986

In Congress: DOD Cancer Research Programs Increased; Senate Passes NIH Funding Bill; Porter Won’t Seek Re-election

October 22, 1999

NCCS Networker Volume 8 Issue 3, Fall 1994

September 12, 1994

Obese Men With Benign Biopsy At High Risk for Prostate Cancer

April 26, 2013

In Brief: Ovarian Cancer Coalition Opens Office; Winchester Leads Surgical Oncologists

July 11, 1997